Devyser has launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution designed to further simplify genetic testing. The improved technology, will help broader screening…
Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4…
Fredrik Alpsten and the Board of Directors of Devyser have now reached an agreement that he will leave his position as CEO of Devyser.Devyser's Board of Directors has initiated the…
In light of this morning’s communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for…
Devyser has received IVDR approval for its non-invasive fetal RHD screening product. This marks the first approval of a Class D product, the highest risk class under the new,…
Devyser Diagnostics AB has appointed a Nomination Committee in preparation for the 2025 Annual General Meeting. The Nomination Committee's task is to present proposals to the meeting…
“It is very gratifying to see the impact that we are having in the field of diagnostics. I have just returned from the ASHI event, a major transplantation conference in the US, and it is…
Devyser has entered an agreement with Thermo Fisher Scientific to collaborate on obtaining U.S. Food and Drug Administration (FDA) approval for One Lambda™ Devyser Accept cfDNA, their…
Devyser has achieved a significant regulatory milestone with its first market registration from China’s National Medical Products Administration (NMPA) for Devyser Compact, an…
Devyser invites investors, analysts and media to a Capital Markets Day on Monday, November 25, 2024 at the company's headquarters in Årsta, Stockholm.
The program will include…
